What should be included in a prenatal appointment at 21 weeks gestation?

21-Week Prenatal Appointment Components

At 21 weeks gestation, the prenatal visit should include a detailed fetal anatomic ultrasound survey, gestational diabetes screening for high-risk patients, blood pressure monitoring, assessment for soft ultrasound markers with appropriate counseling based on prior aneuploidy screening results, and continued routine prenatal surveillance.

Core Components

Fetal Anatomic Assessment

• Detailed fetal anatomic ultrasound examination should be performed between 18-22 weeks gestation, making 21 weeks an optimal timing for this comprehensive evaluation 1
• This examination evaluates fetal structures for major anomalies including central nervous system, cardiac, skeletal, gastrointestinal, and genitourinary systems 1
• If soft ultrasound markers are identified (echogenic intracardiac focus, choroid plexus cysts, echogenic bowel, urinary tract dilation, shortened long bones, thickened nuchal fold, or absent/hypoplastic nasal bone), management depends on prior aneuploidy screening results 2

Soft Marker Management Based on Screening Status

• For patients with negative cell-free DNA or serum screening: isolated echogenic intracardiac focus, choroid plexus cysts, echogenic bowel, urinary tract dilation, or shortened humerus/femur require no further aneuploidy evaluation 2
• For isolated thickened nuchal fold or absent/hypoplastic nasal bone with negative serum screening: counsel regarding probability of trisomy 21 and discuss options for no further evaluation, cell-free DNA testing, or amniocentesis 2
• For isolated echogenic bowel: evaluate for cystic fibrosis and fetal cytomegalovirus infection, with third-trimester ultrasound for growth assessment 2
• For isolated single umbilical artery: no additional aneuploidy evaluation needed; perform third-trimester ultrasound for growth and consider weekly antenatal surveillance starting at 36 weeks 2

Gestational Diabetes Screening

• High-risk patients (marked obesity, personal history of GDM, glycosuria, strong family history of diabetes) who tested negative at initial screening should be retested between 24-28 weeks 3, 4, 5
• At 21 weeks, identify high-risk patients who may benefit from early screening if not previously tested 3
• Average-risk patients should have testing scheduled for 24-28 weeks gestation 3, 4, 5

Blood Pressure and Preeclampsia Risk Assessment

• Measure blood pressure at every visit, with treatment indicated for readings consistently ≥140/90 mm Hg 6
• For patients at high risk of preeclampsia (chronic hypertension, prior preeclampsia, diabetes, renal disease, autoimmune disease), ensure 150 mg daily aspirin was initiated before 16 weeks 6
• Assess for proteinuria if hypertension is present or symptoms suggest preeclampsia 6

Routine Surveillance

• Fundal height measurement to assess fetal growth
• Fetal heart rate assessment by Doppler 7, 8
• Maternal weight and nutritional assessment 8
• Review of symptoms: vaginal bleeding, leakage of fluid, contractions, decreased fetal movement (though quickening may just be starting), headaches, visual changes, right upper quadrant pain 6, 7

Genetic Counseling Considerations

• If not previously addressed, patients ≥35 years at delivery should have received counseling regarding age-related chromosome anomaly risk 9
• Any abnormal first or second trimester maternal serum screening results require discussion of risks and testing options 9
• Patients with teratogen exposures during gestation should receive counseling 9

Immunizations and Screening Status Review

• Confirm completion of recommended vaccinations (influenza, Tdap if not yet given, COVID-19) 8
• Verify completion of first-trimester screening: HIV, syphilis, hepatitis B, rubella immunity, blood type and antibody screen 7, 8
• Ensure asymptomatic bacteriuria screening was completed 7, 8

Common Pitfalls to Avoid

Soft Marker Overinterpretation

• Do not order amniocentesis for isolated soft markers in patients with negative cell-free DNA screening, as the association with aneuploidy is no longer relevant after high-quality screening 2
• Recognize that echogenic intracardiac focus and choroid plexus cysts are normal variants requiring no follow-up when isolated 2

Premature GDM Screening

• Avoid routine GDM screening at 21 weeks in average-risk patients; wait until 24-28 weeks for optimal detection 3, 4, 5
• Only high-risk patients who were negative on early screening need retesting in this window 3

Incomplete Anatomic Survey Follow-up

• If the detailed anatomic survey is incomplete due to fetal position or maternal body habitus, schedule a follow-up ultrasound rather than accepting an incomplete examination 1
• Certain findings (pyelectasis, short long bones, echogenic bowel) require third-trimester follow-up ultrasound even if the fetus is euploid 2, 1